HOME >> BIOLOGY >> NEWS
Advisory panel on federal report on carcinogens makes recommendations to NIEHS/NTP for new listings

An expert advisory panel today recommended to the federal government that steroidal estrogens be listed as a "known" cause of cancer in humans in a future Report on Carcinogens. While panel members said these steroids have important medical uses and clear medical benefits, they have long been associated under certain conditions of use with a risk of uterine and breast cancers. The panel agreed 8 to 1 that these hormones cause an elevated risk and should be considered not merely as associated with increased cancer but as substances that are "known to be a cause of human cancers."

The federal Report on Carcinogens is required by Congress to inform the public, medical community and regulatory agencies about potential cancer-causing substances. It is prepared by the National Toxicology Program, which is headquartered at the National Institute of Environmental Health Sciences in Research Triangle Park, NC. NIEHS/NTP sought the views of the panel of scientists as one step in the development of the Tenth Report on Carcinogens, which will be written and published after further public comment and review.

Estrogens occur naturally in women and to a lesser degree in men. They have important medical uses in hormone replacement therapies in post-menopausal women and for birth control. Their use has long been associated with a risk of uterine, endometrial and breast cancers. They are so labeled, panelists said, and doctors and women should weigh their known benefits against these risks. There was no suggestion by the panelists that medical use of estrogen be restricted or eliminated.

Another medical product, the antibiotic chloramphenicol, was recommended for listing as "reasonably anticipated" to be a cause of human cancer based on evidence of an association with childhood leukemia. Found to be effective against typhus in 1948, it was one of the first antibiotics in large-scale production but after being linked to a risk of potentially fatal aplastic
'"/>

Contact: Bill Grigg 301-492-3378
grigg@niehs.nih.gov
301-492-3378
NIH/National Institute of Environmental Health Sciences
14-Dec-2000


Page: 1 2 3

Related biology news :

1. National Academies Advisory: Sept. 18-19 Nanotechnology Conference
2. National Academies Advisory: June 25 UN public briefing on agriculture in Africa
3. Media Advisory-GSA 2003 Annual Meeting
4. Media Advisory
5. Statement by the Ethics Advisory Board of Advanced Cell Technology, Inc.
6. Media Advisory 2 - 2002 Ocean Sciences Meeting: press conferences scheduled
7. 2002 Ocean Sciences Meeting - Media Advisory 1
8. Intercure Scientific Advisory Board convenes to review companys resperate medical device for hypertension
9. Media Advisory 2: Fall Meeting: Abstracts, press conferences, press registration
10. National Science Foundation Advisory Committee On Environmental Research & Education (ERE) To Meet (October 11-12)
11. Media Advisory: The Geological Society of America 1999 Annual Meeting

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/5/2020)... ... August 05, 2020 , ... Regenative Labs has received approval from the Centers ... making them the first Wharton’s jelly allografts to be assigned a Q code and ... are the first Wharton’s jelly allograft product to be recognized as a 361 HCT/P ...
(Date:7/31/2020)... (PRWEB) , ... July 30, 2020 , ... ... Research (SBIR) Phase II contract awarded by the Joint Science & Technology Office—Chemical ... this project is to develop, optimize, and scale-up a highly efficient mammalian cell ...
(Date:7/22/2020)... Calif. (PRWEB) , ... July 21, 2020 , ... ... driving digital transformation and innovation in technology and compliance, announces a new solution ... device companies must ensure every layer of their technology stack complies with FDA ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... ... August 11, 2020 , ... The FSHD Society announced ... Dystrophy Clinical Trial Research Network (FSHD CTRN), with consideration of follow-on ... consortium of academic research centers in the United States and Europe with expertise ...
(Date:8/12/2020)... ... August 12, 2020 , ... ... (EMMA International), a global leader in FDA compliance consulting has been named on ... private companies. The list represents a unique look at the most successful companies ...
(Date:8/3/2020)... ... August 03, 2020 , ... ERT, the ... CEO has been named one of the 100 most inspiring individuals in the ... honorees are selected based on how they have inspired their colleagues and affected ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is now offering patients ... million stem cells total, patients may choose which extremities they would like treated. , ... (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is obtained from a ...
Breaking Biology Technology:
Cached News: